An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

By Ugur Sahin, P. Oehm, E. Derhovanessian, R. Jabulowsky, M. Vormehr, M. Gold, D. Maurus, D. Schwarck-Kokarakis, A. Kuhn, T. Omokoko and 31 more. Nature, 2020

861 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/4114cc7dc2faed7f0cba4bece628827023d6d9a7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. N-N Xie
2. Zhao Huang
3. Wei Gao
4. Li Fu
5. Guiyuan Li
6. Wei Xiong
7. Zhaoyang Zeng
8. Pan Chen

Citations in the corpus

• Neoantigens: promising targets for cancer therapy (2023, background): “However, as TAAs are non-mutated self-antigens, central T cell tolerance may contribute to the largely poor T cell responses observed in clinical trials.(20,21) Nonetheless, the widespread use of tumor immunotherapies has been hindered by a shortage of targetable antigens in various cancers.”
• Regulatory mechanisms of PD-1/PD-L1 in cancers (2024, background): “The combination of FixVac and anti-PD-1 treatment is particularly effective for patients with a lower mutation burden, with a tumor regression rate exceeding 35% [448].”